Business
SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization
Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and
About this update from Sintx Technologies, Inc.
[{"type":"text","content":"Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025. “We are executing a disciplined transformation that aligns our core capabilities in advanced ceramics with fast-growing, high-impact healthcare applications. This transition positions us for sustainable value creation,” said Eric K. Olson, CEO and President of SINTX Technologies. Refocusing on High-Growth Medical Markets SINTX has accelerated its transition from a diversified industrial-ceramics business to a pure-play medical device innovator. Silicon nitride’s proven biocompatibility, antimicrobial properties, and pro-regenerative properties uniquely position it for: Orthopedic implantsSpinal fusion devicesDental productsMedical Textiles including: wound care, surgical masks, sutures, drapes and other antipathogenic surfaces This strategic redirection aims to address large, underserved clinical needs where infection resistance and osteogenesis and tissue healing are critical. Technology & Market Development Recent scientific and commercial initiatives include: New R&D programs targeting implantable and antipathogenic productsAn active technology pipeline focused on surgical-grade silicon nitride devicesPartnerships and licensing discussions with leading medical OEMsSINTX’s Salt Lake City facility remains only FDA-registered and ISO 13485 certified, silicon nitride ceramic manufacturer Improved Financial Position $6.5 million cash on hand as of March 31, 2025 – nearly doubling from $3.6 million at year-endRecent $5.0 million private placement in February 2025 supported strategic runway along with potential to raise an additional $5.0 million dollars from the exercise of warrants with an exercise price of $3.32 per share of common stockReduced operating cash burn from $2.7M in Q1 2024 to $1.3M in Q1 2025 due to cost optimization Operational Streamlining Sale of non-core subsidiary TA&T to Tethon CorporationWorkforce reduction and shut down of underperforming Armor subsidiaryInitiated negotiations to reduce long-term lease liabilities, particularly at the Armor facility These ...